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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.027Alveolar type II epithelial (ATII) cell injury precedes development of pulmonary ﬁbrosis. Mice lacking
urokinase-type plasminogen activator (uPA) are highly susceptible, whereas those deﬁcient in plasminogen
activator inhibitor (PAI-1) are resistant to lung injury and pulmonary ﬁbrosis. Epithelialemesenchymal
transition (EMT) has been considered, at least in part, as a source of myoﬁbroblast formation during
ﬁbrogenesis. However, the contribution of altered expression of major components of the uPA system on
ATII cell EMT during lung injury is not well understood. To investigate whether changes in uPA and PAI-1
by ATII cells contribute to EMT, ATII cells from patients with idiopathic pulmonary ﬁbrosis and chronic
obstructive pulmonary disease, and mice with bleomycin-, transforming growth factor be, or passive
cigarette smokeeinduced lung injury were analyzed for uPA, PAI-1, and EMT markers. We found reduced
expression of E-cadherin and zona occludens-1, whereas collagen-I and a-smooth muscle actin were
increased in ATII cells isolated from injured lungs. These changes were associated with a parallel increase
in PAI-1 and reduced uPA expression. Further, inhibition of Src kinase activity using caveolin-1 scaf-
folding domain peptide suppressed bleomycin-, transforming growth factor be, or passive cigarette
smokeeinduced EMT and restored uPA expression while suppressing PAI-1. These studies show that
induction of PAI-1 and inhibition of uPA during ﬁbrosing lung injury lead to EMT in ATII cells.
(Am J Pathol 2015, 185: 55e68; http://dx.doi.org/10.1016/j.ajpath.2014.08.027)Supported in part by Flight Attendant Medical Research Institute Clinical
Innovator Award FAMRI-ID-082380 (S.S.), American Heart Association
grant GRNT19020001 (S.S.), and NIH/National Heart, Lung, and Blood
Institute grant HL093547 (S.S.).
Disclosures: None declared.Idiopathic pulmonary ﬁbrosis (IPF) and other interstitial lung
diseases are characterized by destruction of lung architecture
due to excessive deposition of extracellular matrix proteins by
activated ﬁbroblasts or myoﬁbroblasts, leading to progressive
dyspnea and loss of lung function.1e3 The origins of myoﬁ-
broblasts participating in the pathological remodeling of IPF
lungs are not clear. Histopathological evaluation demon-
strates that myoﬁbroblasts accumulate in ﬁbroblastic foci.
Emerging evidence suggests that polarized type II alveolar
epithelial (ATII) cells undergo epithelialemesenchymal
transitions (EMT) after lung injury. The ATII cells assume
phenotypic changes such as increased migration, invasion,
resistance to apoptosis, and production of elevated levels of
extracellular matrix proteins4,5 and therefore serve as a source
of myoﬁbroblasts. Understanding the possible mechanismsstigative Pathology.
.contributing to EMT in ATII cells may help identify new
targets to treat or at least limit ﬁbrogenesis after lung injury.
A number of molecular processes are involved in the
initiation of EMT in ATII cells.5 Components of the ﬁbrino-
lytic system such as urokinase-type plasminogen activator
(uPA), uPA plasmamembrane receptor (uPAR), and its major
inhibitor, plasminogen activator inhibitor (PAI-1) are all
elaborated by ATII cells. These proteins independently in-
ﬂuence a broad range of biological processes germane to lung
injury and its repair.6 However, their role in ﬁbrogenesis via
Marudamuthu et alEMT is unclear. Recent publications using bleomycin
(BLM)7 and a passive cigarette smoke (PCS)8 or adenovirus
expressing constitutively active transforming growth factor b
(Ad-TGF-b)1,9 exposure model of lung injury indicate that a
coordinate increase in PAI-1 and a decrement in uPA by ATII
cells promote lung injury and subsequent pulmonary ﬁbrosis
(PF). We also found that caveolin-1 scaffolding domain
peptide (CSP) acts as a competitor to caveolin-1, restores
expression of uPA and uPAR, and inhibits PAI-1 in ATII cells
after lung injury. These changes prevent development of PF
after lung injury.7 Recent literature suggests that up to 30% to
50% of myoﬁbroblasts may be derived via EMT during
ﬁbrogenesis.10e12 However, an in vivo genetic lineage tracing
study reported by Rock et al13 contradicts these ﬁndings. Our
objective in the current study is to elucidate the role of altered
expression of uPA, uPAR, and PAI-1 after lung injury in
EMT, and further evaluate whether reinstatement of baseline
expression of uPA, uPAR, and PAI-1 by CSP intervention
after lung injury reduces EMT in ATII cells.
Materials and Methods
Isolation and Analysis of ATII Cells from IPF and COPD
Lung Tissues
IPF or chronic obstructive pulmonary disease (COPD), and
control (without overt IPF or COPD) donor lung samples
were collected from patients undergoing thoracic surgery at
St. Mary’s Hospital (Rochester, MN). Protocols were
approved by institutional review boards of Mayo Clinic
(Rochester, MN) and The UT Health Science Center at Tyler
(Tyler, TX). ATII cells were isolated from the IPF, COPD,
and control lung tissues, and aliquots were stained for in-
clusion bodies to assess the purity of cell preparation as we
described recently.8 The lysates from these cells were
immunoblotted for expression of EMT markers. Lung sec-
tions from patients with IPF and COPD, diffused alveolar
damage, or healthy donors were provided by the Lung Tissue
Research Consortium of the National Heart, Lung, and Blood
Institute or by the Department of Pathology at the UT Health
Science Center at Tyler. These sections were subjected to
immunohistochemical (IHC) analysis to assess changes in
antigen levels for uPA, PAI-1, and EMT markers.
BLM- and PCS-Induced Lung Injury
Wild-type (WT) or uPA-, uPAR-, and PAI-1edeﬁcient mice
of C57BL/6 background were bred in our facilities or were
purchased from The Jackson Laboratory (Bar Harbor, ME).
All animal experiments were performed according to approved
protocols under the guidelines of the Animal Care and Use
Committee of The UT Health Science Center at Tyler. For
in vitro experiments, ATII cells were isolated from the lungs of
uninjured mice as we reported elsewhere.7,8 The purities of
ATII cell preparations were approximately 90% to 95%, based
on lithium carbonate staining for inclusion bodies. These cells56were treated with 40 mg/mL BLM with or without 10 nmol/L
CSP or control peptide (CP), or 2 ng/mL puriﬁed TGF-b1
alone in Matrigel-coated culture dishes containing epithelial
cell growthesupplemented alveolar epithelial cell medium
(AEpiCM) from ScienCell Research Laboratories (Carlsbad,
CA) for 3 days.7,8,14e17 For in vivo studies, mice were exposed
to 2 U BLM per kg body weight for 3 days or PCS for 20
weeks with or without 18.75 mg of CSP or CP per kg body
weight as described previously.7,8 ATII cells were isolated and
used for Western blot analysis or real-time PCR analysis to
assess changes in the expression of E-cadherin, ZO-1,
collagen-I, and a-smooth muscle actin (a-SMA) protein and
mRNA, respectively. Real-time PCR using primers for mouse
E-cadherin, forward: 50-AATGGCGGCAATGCAATCCCA-
AGA-30 and reverse: 50-TGCCACAGACCGATTGTGGA-
GATA-30; mouse collagen-I, forward: 50-CCAAGGGTAAC-
AGCGGTGAA-30 and reverse: 50-CCTCGTTTTCCTTC-
TTCTCCG-30; mouse ZO-1, forward: 50-ATTCTGAAGA-
AATGATGAGA-30 and reverse: 50-TCCTGATTGACCA-
CTTTTAA-30; a-SMA, forward: 50-GGCTCTGGGCTCTG-
TAAGG-30 and reverse: 50-CTCTTGCTCTGGGCTTCATC-
30; and b-actin, forward: 50-CACCGCAGCTCGTAGCTCT-
TCTCCAGGG-30 and reverse: 50-CCAGCCATGTACGT-
TGCTATCCAG-30. Lung sections were separately assessed for
collagen-I, E-cadherin, a-SMA, and ZO-1 antigen levels by
IHC analysis. Lung homogenates and bronchoalveolar lavage
ﬂuids of mice exposed to BLMwith or without CSP or CP for 3
days were analyzed for active TGF-b byWestern blot analysis.
The ﬁndings were independently conﬁrmed by enzyme-linked
immunosorbent assay (ELISA) for active TGF-b.
Effect of TGF-b Overexpression on ATII Cell EMT and PF
ATII cells isolated fromWTmice were exposed to Ad-TGF-b
in the presence or absence of 10 nmol/L CSP or CP as
described above. ATII cells untreated or treated with empty
adenovirus (Ad-EV) for 3 days were used as controls. For
in vivo studies, WT mice were exposed to saline or Ad-EV or
Ad-TGF-b (109 plaque forming units) through intranasal
instillation as described earlier.9 After 24 hours, mice exposed
to Ad-TGF-b were treated with or without 18.75 mg CSP or
CP per kg body weight. ATII cells were isolated 3 days after
instillation of Ad-TGF-b and analyzed for changes in EMT.
Lung homogenates of WT mice were analyzed for total hy-
droxyproline contents 21 days after transduction with Ad-
TGF-b to assess changes in PF as we described earlier.7
Effect of p53-Binding uPA, uPAR, and PAI-1 mRNA 30-
UTR Sequences on BLM-Induced ATII Cell EMT in Mice
The competitive inhibition of p53 from binding to endogenous
uPA, uPAR, and PAI-1 mRNAs in ATII cells by over-
expression of p53-binding chimeric uPA, uPAR, and PAI-1 30-
untranslated region (UTR) sequences, concurrently restores
uPA and uPAR, and inhibits PAI-1 expression without
affecting BLM- or PCS-induced p53 in mice.8,18 Therefore,ajp.amjpathol.org - The American Journal of Pathology
uPA-Fibrinolytic System in ATII Cell EMTwe exposed mice to an i.v. (through orbital plexus) injection of
lentivirus vector containing SP-B promoter expressing p53-
binding or nonbinding control chimeric sequences of uPA,
uPAR, and PAI-1 30-UTR mRNA, and the transduction efﬁ-
ciency was conﬁrmed by expression of luciferase in ATII cells
as described previously.18 Twenty-four hours after lentiviral
transduction, these mice were exposed to BLM. ATII cells
were isolated 72 hours after initiation of BLM injury and
analyzed for EMT markers by Western blot analysis.
Effect of Inhibition of uPA or PAI-1 Expression in PAI-
1e and uPA-Deﬁcient ATII Cells, Respectively, on EMT
ATII cells isolated from uninjured mice lacking PAI-1
expression were treated with lentiviral vector expressing
uPA shRNA to inhibit baseline uPA expression. PAI-1e
deﬁcient ATII cells exposed to control shRNA or naive
ATII cells were used as controls. Similarly, ATII cells iso-
lated from uPA-deﬁcient mice were exposed to BLM in the
presence or absence of PAI-1 shRNA or control shRNA.
The lysates from these mice were analyzed for uPA,
E-cadherin, ZO-1, and a-SMA expression.
Generation of Retroviral Plasmid
Retrovirus vector (pLNCX) containing Src mutant Y416F
cDNA was cotransfected with packaging plasmid pUMVC
and auxiliary plasmid pCMV-VSV-G (Addgene, Cam-
bridge, MA) using Lipofectamine 2000 (Life Technologies,
Grand Island, NY) in 293T cells to obtain phage particles.
The viral titers were measured using 293 T cells and later
transduced ATII cells isolated from mouse lungs.
Localization of Biotin-Labeled CSP in Mouse Lungs
To determine the distribution of CSP in the mouse lungs,
mice were exposed to saline or BLM for 72 hours through
intranasal instillation. These mice were i.p. injected with
biotin-labeled CSP. After 24 hours, mice were euthanized,
and the lung sections were analyzed for biotin-labeled CSP
using anti-biotin antibody.
Statistical Analysis
The statistical differences between various experimental
conditions were analyzed by t-test and one way analysis of
variance. P < 0.05 was considered signiﬁcant.
Results
ATII Cell EMT Is Associated with Increased Expression
of PAI-1 and Concurrent Inhibition of uPA in IPF and
COPD Lungs
ATII cell damage precedes development of PF, and restora-
tion of uPA and inhibition of PAI-1 expression preventsThe American Journal of Pathology - ajp.amjpathol.orgdevelopment of PF after ﬁbrosing lung injury in animal
models. Multiple recent studies indicate that EMT in ATII
cells promotes ﬁbrogenesis after lung injury. Therefore, we
isolated ATII cells from the human lung tissues and stained
for inclusion bodies to assess the purity of ATII cell prepa-
ration using lithium carbonate, which indicated purity
approximately 90% to 95% (Figure 1A). Next, we tested the
ATII cell lysates for changes in uPA and PAI-1 expression.
ATII cells isolated from human IPF lungs showed a marked
increase in PAI-1 and reduction in uPA expression compared
to those extracted from histologically normal lungs
(Figure 1B). ATII cells from IPF lungs showed suppression
of epithelial cell markers (E-cadherin and ZO-1) expression,
whereas mesenchymal cell markers (collagen-I and a-SMA)
were increased compared to their baseline expressions found
in control lungs. We also found similar changes in the
expression of uPA, PAI-1, and markers of EMT in ATII cells
from the lungs of patients with COPD. Consistent with the
results of Western blot analysis of isolated ATII cells, IHC
analyses of IPF and COPD lung sections showed increased
collagen-I and inhibition of ZO-1 staining compared to their
expression in control subjects (Figure 1C). Similar changes
were also observed in lung sections of patients with diffused
alveolar damage. This indicates a causal link between altered
ATII cell collagen-I and ZO-1 expression, and EMT as a
result of chronic lung injury.
Effect of CSP on BLM-Induced EMT in ATII Cells
Because ATII cells from human IPF lungs showed increased
EMT and PAI-1 with reduction in uPA expression, we isolated
ATII cells frommouse lungs and exposed them to BLM for 72
hours and analyzed changes in the expression of E-cadherin,
ZO-1, collagen-I, and a-SMA to assess EMT in vitro. Expo-
sure of ATII cells to BLM suppressed expression of E-cad-
herin and ZO-1, while increasing collagen-I and a-SMA
(Figure 2A). ATII cells treated with the proﬁbrogenic cyto-
kine, TGF-b, also revealed a signiﬁcant increase in EMT
compared to phosphate-buffered saline (PBS)-treated control
ATII cells. Exposure of ATII cells to BLM with CSP restored
E-cadherin and ZO-1 expression while signiﬁcantly reducing
the expression of collagen-I and a-SMA. However, the
scrambled CP failed to affect BLM-induced EMT in murine
ATII cells. Because treatment of mouse ATII cells with puri-
ﬁed TGF-b protein increased EMT, we next transduced ATII
cells with Ad-TGF-b in the presence or absence of CSP or CP
and tested for changes in EMT markers. Ad-TGF-b increased
EMT in ATII cells in comparison with those transduced with
Ad-EV (Figure 2B). Further, treatment of ATII cells with CSP,
but not CP, suppressed TGF-beinduced EMT. To determine
whether in vitro culture condition alters phenotypes of ATII
cells during the course of our experiments, we maintained
control ATII cells isolated from uninjured mice in growth
factoresupplemented AEpiCM medium for 0 to 3 days and
analyzed for changes in surfactant proteins by Western blot
analysis. ATII cells cultured in AEpiCM retained baseline57
Figure 1 Altered expressions of plasminogen activator inhibitor (PAI-1) and urokinase-type plasminogen activator (uPA) are associated with alveolar type
II (ATII) cell epithelialemesenchymal transition in idiopathic pulmonary ﬁbrosis (IPF) and chronic obstructive pulmonary disease (COPD) lungs. A: ATII cells
isolated from lung explants were stained for inclusion bodies using lithium carbonate to assess the purity of the cell preparation. B: ATII cells isolated from
patients (nZ 3) with IPF (gray bars) or COPD (white bars) and from healthy donors. The lysates were analyzed for changes in the expression of uPA, PAI-1,
collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin. The fold changes in densities of individual bands are presented as a bar graph after normalization against
the corresponding densities of b-actin antigens present in each sample. C: Parafﬁn-embedded sections from lung tissues of patients with IPF or COPD or
diffused alveolar damage (DAD) and healthy donors were subjected to IHC analysis for changes in collagen-I and ZO-1 antigen levels in situ. Representative
photomicrograph (from n Z 5) is shown. ****P < 0.0001.
Marudamuthu et alSP-A, SP-B, and SP-C expression at least for 3 days, indi-
cating preservation of cellular phenotypes (Figure 2C).
Next, we exposed the mice to BLM through intranasal
instillation, and some mice were exposed to CSP or CP 24
hours after initiation of BLM injury. Saline-treated mice
were used as controls. The lung sections from these mice
were subjected to IHC analysis for changes in EMT markers
in situ. Following BLM-induced injury, lung sections of
mice showed a marked inhibition of ZO-1 antigen expres-
sion, whereas collagen-I antigen levels were markedly
increased in the lung parenchyma (Supplemental Figure S1).
Further, treatment of mice with CSP markedly reduced
BLM-induced EMT, which was conﬁrmed by the changes
in ZO-1 or collagen-I expression, whereas the response of
CP to BLM-induced EMT was negative. Because PCS
exposure causes lung injury, albeit to a lesser extent than
BLM-induced lung injury in mice,7,8 and ATII cells isolated
from patients with COPD also showed increased EMT
(Figure 1, B and C), we exposed mice to PCS and analyzed
the lung sections for changes in markers for EMT. PCS
exposure increased collagen-I with concurrent suppression
of ZO-1 expression (Supplemental Figure S2). However,
treatment with CSP markedly reversed PCS-induced
changes in the EMT markers.58To further show these changes for alveolar epithelium, we
isolated ATII cells from mice exposed to BLM (Figure 2D)
or PCS (Figure 2E) and analyzed for changes in expression
of EMT markers. ATII cells collected from mice exposed to
intranasal BLM or PCS showed increased expression of
collagen-I and a-SMA, whereas epithelial cell markers such
as E-cadherin and ZO-1 were signiﬁcantly suppressed
compared to baseline levels in mice without lung injury
(Figure 2, D and E). Further, treatment of mice with CSP
after BLM or PCS exposure injury signiﬁcantly prevented
EMT. We next evaluated changes in E-cadherin, ZO-1,
collagen-I, and a-SMA expression at the mRNA level.
Consistent with protein expression and mRNA analysis by
quantitative real-time PCR, the results indicated that BLM
injury increased EMT (Figure 2F). In addition, treatment of
mice with CSP attenuated BLM-mediated induction of
collagen-I and a-SMA mRNA, and restored the expression
of E-cadherin and ZO-1 mRNA in ATII cells. There were no
signiﬁcant changes in the expression of EMT markers in
BLM-injured mice treated with CP. Because TGF-b induces
EMT in ATII cells in vitro (Figure 2B), and is a major
mediator of ﬁbrosis in diverse organs, including lungs,19,20
we next tested whether CSP reverses ATII cell EMT in
mice exposed to Ad-TGF-b. We found increased EMT inajp.amjpathol.org - The American Journal of Pathology
Figure 2 Inhibition of bleomycin (BLM)-induced epithelialemesenchymal transitions (EMT) in ATII cells by caveolin-1 scaffolding domain peptide (CSP).
A: ATII cells isolated from WT mice were treated with PBS or 40 mg/mL BLM alone or BLM with 10 nmol/L CSP or control peptide (CP) for 72 hours in culture
dishes at 37C. The lysates were immunoblotted for changes in the expression of collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin antigens. The lysates from
ATII cells treated with 2 ng/mL transforming growth factor b (TGF-b) were used as a positive control for comparison. The densities of individual bands were
normalized against the corresponding densities of b-actin. The fold changes in proteins are presented as a bar graph. Differences between PBS control and BLM
or BLM and BLMþCSP groups are statistically signiﬁcant. B: ATII cells isolated from WT mice were exposed to PBS, Ad-EV, or Ad-TGF-b with or without CSP or
CP in culture dishes. After 72 hours, the lysates were analyzed for changes in EMT markers by Western blot analysis. C: ATII cells isolated from WT mice were
cultured in Matrigel-coated plastic dishes for 0 to 3 days at 37C. The lysates were later analyzed for changes in SP-A, SP-B, and SP-C expression by Western
blot analysis. D: WT mice were exposed to saline or 2 U/kg body weight BLM through intranasal instillation. After 24 hours, mice exposed to BLM were i.p.
injected with or without 18.75 mg/kg body weight of CSP or CP. Three days after BLM injury, ATII cells were isolated and the lysates were immunoblotted for
changes in the expression of collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin. The densities of individual bands were measured and normalized against the
corresponding densities of b-actin. The fold changes in proteins are presented as a bar graph. E: WT mice were exposed to ambient air or PCS from 40
cigarettes (approximately 90 mg/m3 total solid particulates) using a mechanical smoking chamber over a 2-hour period for 5 days per week. After 4 weeks of
PCS exposure, mice exposed to PCS were i.p. injected with or without 18.75 mg/kg body weight of CSP or CP once every week for 4 more weeks. After 20 weeks
of PCS exposure, ATII cells were isolated, and the lysates were tested for changes in the expression of collagen-I, a-SMA, E-cadherin, ZO-1 and b-actin by
Western blot analysis. F: Total RNA isolated from ATII cells of mice treated with saline, BLM, BLMþCSP, or CP were analyzed for changes in the expression of
E-cadherin, collagen-I, ZO-1, and a-SMA mRNAs by quantitative real-time PCR. Changes in their expression levels were normalized to the corresponding levels
of b-actin transcripts. The data were presented relative to that of saline-treated control groups. G: WT mice were exposed to saline, Ad-EV, or Ad-TGF-b by
intranasal instillation. Twenty-four hours later, mice transduced with Ad-TGF-b were treated with or without CSP or CP. ATII cells were isolated from these mice
72 hours after exposure to TGF-b and analyzed for changes in EMT markers by Western blot analysis. H: WT mice treated with Ad-EV or Ad-TGF-b alone or Ad-
TGF-b with CSP or CP as described in G were euthanized 21 days after initial transduction with Ad-TGF-b. The lung homogenates were analyzed for total
hydroxylproline contents to assess changes in lung ﬁbrosis. I: Mice were i.v. (via orbital plexus) injected with or without lentivirus expressing p53-binding or
nonep53-binding control chimeric 30-UTR sequences of uPA/uPAR/PAI-1 mRNA 30-UTR as described elsewhere.14 Twenty-four hours later, the mice were
exposed to BLM, and ATII cells were isolated 72 hours after inception of BLM injury. ATII cells isolated from mice exposed to saline were used as control for
comparison. The lysates were tested for changes in the expression of collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin. ****P < 0.0001 versus control.
uPA-Fibrinolytic System in ATII Cell EMTATII cells from mice transduced with Ad-TGF-b compared
to those exposed to Ad-EV (Figure 2G). Consistent with
BLM-induced injury, treatment of mice exposed to Ad-
TGF-b with CSP, but not CP, suppressed EMT in ATII
cells. Further analysis of lung tissues for total hydroxypro-
line contents conﬁrmed increased PF in mice exposed to
Ad-TGF-b 21 days later (Figure 2H). This was signiﬁcantlyThe American Journal of Pathology - ajp.amjpathol.orgsuppressed in mice exposed to Ad-TGF-b and later treated
with CSP.
ATII cells isolated from IPF and COPD showed increased
EMT associated with a parallel increase in PAI-1 and inhibi-
tion of uPA expression (Figure 1). p53 concurrently inhibits
uPA and uPARwhile inducing PAI-1 expression in ATII cells
during BLM or PCS exposure injury by binding unique59
Marudamuthu et al30-UTR sequences.7,8,18 CSP inhibits BLM- or PCS-induced
ATII cell injury and prevents BLM-induced development of
PF. The process involves inhibition of p53 expression and
reversal of p53-mediated downstream changes in uPA, uPAR,
and PAI-1. To independently conﬁrm whether p53-mediated
changes in uPA, uPAR, and PAI-1 expression in ATII cells
contribute to EMT after BLM lung injury, we transduced
mouse lung ATII cells with lentivirus expressing p53-binding
sequences under the control of SP-B promoter in vivo. These
mice were later exposed to BLM, and ATII cells were isolated
and tested for changes in EMT. Overexpression of p53-
binding 30-UTR sequences signiﬁcantly suppressed BLM-
induced EMT in ATII cells (Figure 2I). However, mice
exposed to control sequence showed increased EMT in ATII
cells after exposure to BLM.
Role of uPA in CSP-Mediated Inhibition of
BLM-Induced ATII Cell EMT
ATII cells from COPD and IPF lungs showed reduction in
uPA expression (Figure 1). Studies suggests that mice
lacking uPA expression are highly susceptible to BLM-
induced PF. We further found that treatment of uPA-
deﬁcient mice with CSP after BLM injury failed to pre-
vent the development of PF.7 To determine whether CSP-
mediated inhibition of ATII cell EMT in WT mice
required restoration of uPA expression, we isolated ATII
cells from uninjured uPA-deﬁcient mice. The purity of ATII
cell preparation was conﬁrmed by lithium carbonate stain-
ing for inclusion bodies (Supplemental Figure S3A). These
cells were treated with BLM in the presence or absence of
CSP or CP in vitro. Treatment of uPA-deﬁcient mouse ATII
cells with either BLM or TGF-b in vitro, signiﬁcantly
induced EMT (Figure 3A). Interestingly, unlike WT ATII
cells, ATII cells lacking uPA expression with BLM injury
failed to respond to CSP treatment. Our results suggest that
restoration of uPA expression after BLM injury is critical in
the control of EMT.
We then exposed uPA-deﬁcient mice to BLM with or
without CSP or CP, and analyzed the lung tissues for EMT in
situ by IHC. uPA-deﬁcient mice exposed to BLM showed
increased expression of collagen-I and a-SMA, whereas ZO-1
antigen levels were signiﬁcantly reduced after BLM injury
(Supplemental Figure S4). Interestingly, unlike WT mice,
uPA-deﬁcient mice with BLM-induced lung injury failed to
respond to CSP treatment. Analysis of isolated ATII cells from
these mice, for changes in the expression of EMT markers by
Western blot analysis, indicated an increased EMT compared
to their baseline levels in uPA-deﬁcient mice without lung
injury (Figure 3B). Treatment of uPA-deﬁcient mice with
either CSP or CP after BLM injury failed to reverse ATII cell
EMT that was due to BLM injury. mRNA analyses for
changes in the expression of EMT markers in uPA-deﬁcient
mice with BLM injury further conﬁrmed that CSP failed to
restore their expression (Figure 3C). These data indicate the
importance of uPA expression by ATII cells to prevent EMT60during BLM-induced lung injury. The literature21,22 suggests
that uPA through plasmin generation can activate extracellular
matrixetrapped TGF-b, whereas ATII cells lacking uPA
expression resist CSP-mediated suppression of EMT after
BLM injury. Therefore, we analyzed lung homogenates and
bronchoalveolar lavage ﬂuids from WT and uPA-deﬁcient
mice for active TGF-b by Western blot analysis (Figure 3D)
and ELISA (Figure 3E). Our results conﬁrmed that BLM lung
injury increased active TGF-b levels inWT and uPA-deﬁcient
mice, which was signiﬁcantly suppressed in WT mice with
BLM injury exposed to CSP.
Role of uPAR in ATII Cell EMT
Because most of the cellular functions of uPA are dependent
on its binding to uPAR, we also isolated ATII cells from
uPAR-deﬁcient mice, conﬁrmed the purity by lithium car-
bonate staining for inclusion bodies (Supplemental
Figure S3B), and used these cells to study the role of
uPAR in EMT. Consistent with the responses of WT and
uPA-deﬁcient ATII cells, ATII cells lacking uPAR showed
increased EMT following exposure to BLM. Treatment with
either CSP or CP failed to signiﬁcantly attenuate EMT
induced in ATII cells because of BLM (Figure 4A). To
further conﬁrm the above ﬁndings in vivo, we exposed
uPAR-deﬁcient mice to BLM and treated them with CSP or
CP. ATII cells were isolated and analyzed for changes in
EMT markers. Reduced E-cadherin and ZO-1 with increased
collagen-I and a-SMA expression indicated EMT in ATII
cells isolated from mice after BLM injury (Figure 4B).
Further, uPAR-deﬁcient mice exposed to BLM resisted CSP
treatment and showed increased ATII cell EMT. The ana-
lyses of ATII cells for changes in E-cadherin, ZO-1,
collagen-I, and a-SMA mRNAs further proved that ATII
cell-speciﬁc uPAR expression is also required for CSP to
inhibit BLM-induced EMT (Figure 4C).
Role of PAI-1 Expression in ATII Cell EMT
PAI-1 expression is increased during BLM- or PCS-induced
lung injury, and mice that lack PAI-1 expression resist ATII
cell injury and subsequent development of PF.7,8 We
investigated whether PAI-1 expression contributes to EMT
in ATII cells. ATII cells lacking PAI-1 when exposed to
BLM in vitro, resisted inhibition of E-cadherin and ZO-1
(Figure 5A). Interestingly, baseline expression levels of
collagen-I and a-SMA in PAI-1edeﬁcient ATII cells
without BLM injury were highly elevated and comparable
with WT ATII cells with BLM injury (Figure 2A). How-
ever, treatment of PAI-1edeﬁcient ATII cells with BLM
alone, or BLMþCSP, or BLMþCP failed to signiﬁcantly
alter the baseline levels of E-cadherin, ZO-1, collagen-I, and
a-SMA expression.
Analysis of ATII cells isolated from the lungs of PAI-1e
deﬁcient mice exposed to BLM showed little inhibition of
basal E-cadherin and ZO-1 expression in vivo (Figure 5B).ajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Role of urokinase-type plasminogen activator (uPA) in ATII cell epithelialemesenchymal transitions after bleomycin (BLM) injury. A: ATII cells
isolated from mice deﬁcient in uPA expression were treated with PBS, BLM, BLMþCSP, or BLMþCP in vitro. The lysates were tested for the expression of
collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin antigens by Western blot analysis. The lysates from uPA-deﬁcient ATII cells treated with TGF-b were used as a
control for comparison. The individual bands were quantitated and normalized to the corresponding values of b-actin loading controls and the fold changes in
proteins are presented as a bar graph. Differences between treatments versus control are statistically signiﬁcant. B: Mice deﬁcient in uPA expression were
exposed to saline or BLM as described in Figure 2D. Twenty-four hours after initial exposure to BLM, mice were i.p. injected with or without caveolin-1
scaffolding domain peptide (CSP) or control peptide (CP). Seventy-two hours after initiation of BLM injury, ATII cells were isolated and the lysates were
evaluated for changes in the expression of collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin by Western blot analysis. The densities of individual bands were
normalized against the corresponding densities of b-actin protein, and the fold changes in proteins are presented as a bar graph. C: Total RNA isolated from
ATII cells of uPA-deﬁcient mice exposed to saline, BLM, BLMþCSP, or CP were analyzed for changes in the expression of E-cadherin, collagen-I, ZO-1, and
a-SMA mRNA levels by real-time PCR. The data were normalized with corresponding levels of b-actin mRNA. The fold changes of mRNA are presented as a bar
graph. D: The lung homogenates of WT and uPA-deﬁcient mice exposed to saline, BLM, BLMþCSP, or BLMþCP were tested for active TGF-b by Western blot
analysis. E: The bronchoalveolar lavage ﬂuids (BALF) of WT and uPA-deﬁcient mice exposed to saline, BLM, BLMþCSP, or BLMþCP were analyzed for active
TGF-b byELISA. ****P < 0.0001 versus control (A, D, E, and F).
uPA-Fibrinolytic System in ATII Cell EMTSimilarly, in mice lacking PAI-1 expression, BLM failed to
augment baseline levels of collagen-I and a-SMA, which
were unusually high in ATII cells. Treatment of PAI-
1edeﬁcient mice, exposed to BLM with either CSP or CP,
failed to affect baseline expression of E-cadherin, ZO-1,
collagen-I, and a-SMA further. Analysis of ATII cell
mRNA for EMT markers (Figure 5C) likewise demonstrated
resistance of PAI-1edeﬁcient mice to BLM.
Mice deﬁcient in uPA expression exhibit increased EMT
and develop PF after BLM injury, whereas those lacking
PAI-1 resist both EMT and PF. Therefore, we next inhibited
uPA expression in ATII cells obtained from PAI-1edeﬁcient
mice to determine whether increased uPA expression, as a
result of a lack of PAI-1, provided resistance against BLM-
induced EMT. Inhibition of uPA expression by at least 75% toThe American Journal of Pathology - ajp.amjpathol.org80% using shRNA failed to alter E-cadherin, ZO-1, collagen-I,
and a-SMA expression in PAI-1edeﬁcient ATII cells
(Figure 5D). On the contrary, inhibition of PAI-1 expression
using shRNA in uPA-deﬁcient ATII cells resisted BLM-
induced EMT, supporting the pivotal role played by
increased PAI-1 expression in the induction of ATII cell EMT.
Role of Activation of Src Kinase in BLM-Induced ATII
Cell EMT
BLM and TGF-b lung injuries increase Src kinase activation
and induction of PAI-1 expression is further dependent on
activation of Src kinases.23 To investigate the involvement of
Src kinase activation in ATII cell EMT, we tested ATII cell
lysates for changes in the phosphorylation of tyrosine residues61
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Figure 4 Effect of uPA plasma membrane receptor (uPAR) expression on bleomycin (BLM)-induced ATII cell epithelialemesenchymal transitions. A: ATII
cells isolated from mice lacking uPAR expression were exposed to PBS, BLM, BLMþCSP, or BLMþCP in vitro. The lysates were immunoblotted for the expression
of collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin antigens. The lysates from uPAR-deﬁcient ATII cells treated with transforming growth factor b (TGF-b)
were used as a control. The densities of individual bands were compiled and normalized against corresponding values of b-actin loading controls. The fold
changes in proteins are presented as a bar graph, and the differences between treatments versus control were statistically signiﬁcant. B: uPAR-deﬁcient mice
were treated with saline or BLM and 24 hours after the initial exposure to BLM, mice with BLM injury were i.p. injected with or without caveolin-1 scaffolding
domain peptide (CSP) or control peptide (CP). Three days after the initiation of BLM injury, ATII cells were isolated from these mice, and the cell lysates were
immunoblotted for altered expression of collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin. The fold changes of proteins are presented as a bar graph. C: ATII cell RNA
from uPAR-deﬁcient mice exposed to saline, BLM, BLMþCSP, or CP were tested for changes in the expression of E-cadherin, collagen-I, ZO-1, and a-SMA mRNAs by
real-time PCR. The fold changes of mRNA are presented as a bar graph. ****P < 0.0001 versus control.
Marudamuthu et al418 (Y418) and 527 (Y527). We found that ATII cells isolated
fromWT (Figure 6A), uPA-deﬁcient (Figure 6B), and uPAR-
deﬁcient (Figure 6C) mice exposed to BLM show increased
Y418 phosphorylation, indicating activation of Src kinase. This
was reversed after treatment of WT mice with CSP through
inhibitory phosphorylation (Y527) of Src kinase. However,
treatment of uPA- or uPAR-deﬁcient mice with CSP failed to
inhibit BLM-induced activation of Src kinase (Figure 6, B and
C) or EMT (Figures 3 and 4). Interestingly, BLM failed to
increase phosphorylation of Y418 and inhibit phosphorylation
of Y527 Src kinases from baseline levels observed in control
mice lacking PAI-1 expression (Figure 6D). Our data therefore
suggest that induction of Src activation in ATII cells by BLM
contributes to EMT. This is reversed by CSP-mediated
inhibitory (Y527) phosphorylation of Src kinases. The pro-
cess involves inhibition of BLM-induced PAI-1 expression
and restoration of baseline levels of uPA and uPAR
expression.
Microscopic examination of lung sections of mice i.p.
injected with biotin-labeled CSP revealed that the peptide
CSP was predominantly distributed in the alveolar and
airway epithelium of the BLM-injured lungs compared with
uninjured epithelium of the saline-treated lungs. This in-
dicates that the lung injury facilitates CSP adsorption
(Supplemental Figure S5).
To further conﬁrm that BLM-induced activation of Src ki-
nase contributes to ATII cell EMT, we treated ATII cells with
BLM in the presence of Src kinase inhibitor PP2,24 and the
control cells received PP3. Inhibition of Src activation
signiﬁcantly suppressed BLM-induced EMT in ATII cells
(Figure 6E). These changes were associated with parallel in-
hibition of BLM-induced PAI-1 expression and restoration of62uPA expression. Because BLM induces Src activation through
Y418, we transduced ATII cells with dominant-negative Y418F
mutant Src kinase and exposed these cells to BLM. The lysates
were tested for changes in EMTmarkers. Our data indicate that
transduction of ATII cells with Y418F mutant Src kinase failed
to induce EMT after exposure to BLM (Figure 6F). Because
activated Src kinase phosphorylates caveolin-1 during renal
epithelial cell EMT,25,26 and CSP inhibits activation of Src
kinase, we analyzed ATII cells for changes in total and Y14
phosphorylated caveolin-1. BLM injury increased both total
and Y14 phosphorylated forms of caveolin-1 in ATII cells of
WT and uPA-deﬁcient mice (Figure 6G). However in WT
mice, CSP suppressed Y14 phosphorylation of caveolin-1
probably through inhibition of Src kinase activation without
affecting total caveolin-1, which is otherwise increased after
BLM lung injury. Interestingly, CSP failed to suppress Src
activation or Y14 phosphorylation of caveolin-1 in uPA- or
uPAR-deﬁcient mice, indicating the inevitability of CSP-
mediated uPA and uPAR expression in inactivation of Src
kinase through Y527 phosphorylation7 and downstream Y14
phosphorylation of caveolin-1. Consistent with Src activation,
BLM or BLMþCSP failed to alter the baseline expression of
the total or Y14 phosphorylated caveolin-1 level in PAI-1e
deﬁcient mice.
The expression of TGF-b, a proﬁbrotic cytokine that in-
duces EMT in ATII cells, was signiﬁcantly increased after
BLM injury and is a major contributor to the development
of PF in multiple organs, including lungs. We therefore
exposed the ATII cells to TGF-b alone or TGF-b in the
presence of TGF-b receptor kinase inhibitor (SB-431542)27
and found that TGF-b increased EMT, indicated by the
changes in the markers as well as Src activation (Figure 6H).ajp.amjpathol.org - The American Journal of Pathology
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Figure 5 The contribution of plasminogen activator inhibitor (PAI-1) in bleomycin (BLM)-induced ATII cell epithelialemesenchymal transitions (EMT). A:
ATII cells isolated from PAI-1edeﬁcient mice were treated with PBS, BLM, BLMþCSP, or BLMþCP in vitro. The lysates were immunoblotted for changes in
collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin expression. The lysates from ATII cells lacking PAI-1 expression that were treated with transforming growth
factor b (TGF-b) were used as a control. The individual densities of bands were quantitated and normalized to the corresponding values of b-actin. The fold
changes in protein expression are presented as a bar graph. Differences between treatments versus control are not statistically signiﬁcant. B: Mice lacking PAI-1
expression were treated with saline or BLM, and 24 hours later, mice exposed to BLM were i.p. injected with or without caveolin-1 scaffolding domain
peptide (CSP) or control peptide (CP). Three days after initiation of BLM injury, ATII cells were isolated from saline, BLM-, BLMþCSP-, or BLMþCP-treated
mice. The lysates were examined for the expression of collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin by Western blot analysis. The densities of bands
were normalized against the corresponding levels of b-actin. The bar graph represents the fold change of proteins. C: Total RNA isolated from ATII cells of
PAI-1edeﬁcient mice exposed to saline, BLM, BLMþCSP, or CP were analyzed for changes in the expression of E-cadherin, ZO-1, collagen-I, and a-SMA
mRNA levels by real-time PCR. The data were normalized with corresponding levels of b-actin mRNA. The fold changes of RNA are presented as a bar graph.
D: ATII cells isolated from PAI-1edeﬁcient or uPA-deﬁcient mice were treated with lentivirus expressing uPA or PAI-1 shRNA. ATII cells obtained from both
uPA-deﬁcient and PAI-1edeﬁcient mice exposed to nonspeciﬁc shRNA or naive ATII cells were used as controls for comparison. Because BLM injury causes
EMT in uPA-deﬁcient mice, whereas those lacking PAI-1 expression resist BLM-induced EMT, ATII cells from uPA-deﬁcient mice treated with or without
PAI-1 shRNA or control shRNA were later exposed to BLM for 72 hours. The lysates from PAI-1edeﬁcient and uPA-deﬁcient ATII cells were analyzed for
changes in EMT markers by Western blot analysis.
uPA-Fibrinolytic System in ATII Cell EMTThese changes were associated with parallel induction of
PAI-1 and inhibition of uPA. However, inhibition of TGF-b
receptor kinase signiﬁcantly suppressed TGF-beinduced
EMT, expression of PAI-1, and activation of Src kinase with
restoration of baseline uPA expression.The American Journal of Pathology - ajp.amjpathol.orgDiscussion
uPA is mainly involved in extravascular proteolysis and tissue
remodeling.28e30 uPAR, a glycosylphosphatidylinositol-
linked receptor, is implicated in multiple uPA-mediated63
EB DC
- + + + -
- - + - -
- - - + -
- - - - +
- + + + -
- - + - -
- - - + -
- - - - +
SB-431542   -   -    + 
  -   +   + 
PAI-1
uPA
E-Cadherin
ZO-1
Collagen-I
P-Y418-SRC
P-Y527SRC
SRC
- + + + -
- - + - -
- - - + -
- - - - +
A
BLM
CSP
CP
- + + + -
- - + - -
- - - + -
- - - - +TGF-β
TGF-β
SRC
β-actin 
P-Y418SRC
P-Y527SRC
F
PAI-1
uPA
E-Cadherin
ZO-1
Collagen-I
α-SMA
α-SMA
α-SMA
β-actin
β-actin
β-actinβ-actin-
P-Y418-SRC
PP2
BLM
PP3
  -   +   +   +
  -   -    -    +
  -   -    +   -
SRC
E-Cadherin
ZO-1
P-Y418-SRC
SRC
- + - +
+ + - -
- - + +
BLM
EV
SrcY418F
BLM
PAI-1
–/–
G H
P-Cav-1-
Sa
lin
e
N
on
e
C
SP
C
P
Sa
lin
e
N
on
e
C
P
BLM BLM
WT uPA
–/–
C
SP
Cav-1-
Sa
lin
e
N
on
e
C
P
BLM
uPAR
–/–
C
SP
Sa
lin
e
N
on
e
C
P
C
SP
Figure 6 Effect of tyrosine phosphorylation of Src kinases on bleomycin (BLM)-induced ATII cell epithelialemesenchymal transitions (EMT) in WT, urokinase-
type plasminogen activator (uPA)-, uPA plasma membrane receptor (uPAR)-, and plasminogen activator inhibitor (PAI-1)edeﬁcient mice. AeD: ATII cells
isolated from WT (A), uPA-deﬁcient (B), uPAR-deﬁcient (C) and PAI-1edeﬁcient (D) mice were treated with saline or BLM with or without caveolin-1 scaffolding
domain peptide (CSP) or control peptide (CP) in culture dishes. The lysates were tested for changes in the phosphorylation of tyrosine (Y418 and Y527) residues of
Src kinases by Western blot analysis using phospho-speciﬁc antibodies. The samemembrane was stripped and tested for total Src kinase and b-actin proteins. ATII
cell lysates treated with TGF-b were also used as controls. E: ATII cells were treated with PBS, BLM, BLM in the presence of 10 mmol/L Src kinase inhibitor PP2 or
control PP3 in culture dishes for 72 hours. The lysates were tested for changes in tyrosine Y418 phosphorylation of Src kinases, PAI-1, uPA, collagen-I, a-SMA,
E-cadherin, ZO-1, and b-actin by Western blot analysis. F: ATII cells isolated from WT mice were transduced with retrovirus expressing dominant-negative Y418F
mutant Src kinase. ATII cells from WT mice exposed to empty vector (EV) were used as controls for comparison. After 24 hours, these cells were treated with BLM,
and the lysates were analyzed for changes in EMT markers 72 hours after BLM injury. WT ATII cells treated with PBS or BLM alone were used as controls. The lysates
were analyzed for changes in EMT markers. G: ATII cells isolated fromWT and uPA-deﬁcient mice were exposed to saline or BLM or BLM with CSP or CP for 72 hours,
and the lysates were immunoblotted for total and phosphorylated caveolin-1 (P-Cav-1), and b-actin using speciﬁc antibodies. H: ATII cells were treated with PBS,
TGF-b, or TGF-b in the presence of 10 mmol/L inhibitor of TGF-b receptor kinase (SB-431542) in culture dishes for 72 hours. The lysates were immunoblotted for
changes in tyrosine phosphorylation of Src kinases, PAI-1, uPA, collagen-I, a-SMA, E-cadherin, ZO-1, and b-actin by Western blot analysis.
Marudamuthu et alcellular functions. Bronchoalveolar lavage ﬂuids normally
contain high levels of uPA activity, but it is markedly reduced
in patients with IPF, COPD, sarcoidosis, and adult respiratory
distress syndrome,2,31,32 as well as in mice with BLM- and
PCS-induced lung injury because of increased local expression
of PAI-1.7,33 Proinﬂammatory stimuli such as TNF-a and64TGF-b augment uPA, uPAR, and PAI-1 expression, and
PAI-1 inhibits uPA activity and promotes cycling of uPAe
uPARePAI-1.30 Lung epithelial cells are often targets of acute
and chronic lung injuries and a key driver of normal repair
because of their constant contact with the outside environment
and their ability to suppress ﬁbroblast growth.34ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Regulation of ATII cell epithelialemesenchymal transitions
(EMT) and pulmonary ﬁbrosis (PF) through p53euPAeﬁbrinolytic system
cross talk. Increased expression and phosphorylation of caveolin-1 by
activated Src kinases augments p53 expression in ATII cells during ﬁbrosing
lung injury. p53 in turn binds to urokinase-type plasminogen activator
(uPA), uPA plasma membrane receptor (uPAR), and plasminogen activator
inhibitor (PAI-1) mRNAs leading to suppression of uPA and uPAR, and
increased PAI-1 expression.49e51 This results in enhanced ATII cell EMT and
development of PF. Inhibition of p53 interaction with endogenous uPA,
uPAR, and PAI-1 mRNA in ATII cells either by inhibiting p53 expression
using CSP or competitive inhibition through overexpression of p53-binding
30-UTR sequences of uPA, uPA, and PAI-1 mRNA restores uPA, uPAR, and
PAI-1 expression and mitigates ATII cell EMT and development of PF after
ﬁbrosing lung injury.
uPA-Fibrinolytic System in ATII Cell EMTIPF is one of the most common forms of interstitial lung
diseases, characterized by apoptosis of ATII cells, alveolar
ﬁbrin deposition, depressed ﬁbrinolysis, inﬂammation,
myoﬁbroblast accumulation, and progressive loss of lung
function as a result of accumulation of extracellular matrix
proteins.2,35,36 Myoﬁbroblasts play a vital role in ﬁbro-
genesis after lung injury. The literature suggests that myo-
ﬁbroblasts arise from activation of resident lung ﬁbroblasts,
from differentiation of bone-marrowederived stromal cells
and also from ATII cells via EMT.1,37,38 Other reports
suggest increased expression of mesenchymal marker pro-
teins and mRNAs by hyperplastic ATII cells in human IPF
lungs4 and that approximately 30% to 50% of ﬁbroblasts are
also derived via EMT in BLM-induced lung injury.11 This
supports the importance of transformation of ATII cells into
myoﬁbroblasts via EMT in the pathogenesis of PF12 in
addition to apoptosis of ATII cells.7,8 Most recent in vivo
genetic lineage tracing studies using single-dose BLM in
mice13 suggest that epithelial cells do not generate myoﬁ-
broblasts, thus undermining the importance of EMT in the
context of PF. However, others studies using a mouse model
of either a single dose or repeated doses of BLM-induced
lung injury indicate that EMT promotes ﬁbro-
genesis.11,39,40 The discrepancies between studies could be
technical, which is beyond the scope of the present study.
Irrespective of whether or not reversible phenotypic
changes, such as EMT in ATII cells during lung injury,
contribute to ﬁbrosis, ATII cells in IPF and COPD lungs
show EMT with elevated PAI-1 and concurrent suppression
of uPA. Recently, Wang et al41 showed association of
epithelial overexpression of uPAR with EMT in COPD
lungs. Although CS is a risk factor for lung ﬁbrosis,42,43 it is
a major contributor for lung carcinogenesis, and mice
exposed to CS do not develop lung ﬁbrosis despite the
increased EMT. In addition, increased senescence and
apoptosis, rather than excess proliferation, of lung epithelial
cells are hallmarks of COPD. Further, uPA and uPAR
provides proproliferative and prosurvival signals in diverse
cell types, including lung epithelial cells,44,45 and mice
lacking uPA or uPAR resist tumor growth,46 whereas uPA
and uPAR deﬁciency, rather than overexpression, contrib-
utes to multiple organ ﬁbrosis, including PF. This is further
supported by the fact that lung injuries, including BLM- or
CS-induced lung injury, are often associated with reduced
uPA and uPAR expression because of excess expression of
PAI-1 and PAI-1emediated turnover of the uPAeuPAR
complex.18,47 Besides, DNA damage caused by BLM or CS
or other injuries augments p53 in airway epithelial cells. p53
in turn concurrently inhibits uPA and uPAR while inducing
PAI-1 expression both at the transcriptional48,49 and post-
transcriptional levels.50e52 Therefore, EMT associated with
increased uPAR in COPD lungs may be more related to
carcinogenesis than ﬁbrosis of lungs or other organs.41
We further found that BLM-, TGF-be, and PCS-induced
lung injury drives ATII cells to EMT and, later, BLM- and
TGF-beinduced PF in WT and uPA-deﬁcient mice,The American Journal of Pathology - ajp.amjpathol.orgwhereas PAI-1edeﬁcient mice resist EMT and PF. We
found that tissues, as well as isolated ATII cells from the
lungs of WT mice with BLM- or PCS-exposure injury,
show induction of PAI-1, and reciprocal suppression of uPA
and uPAR expression and apoptosis.7,8,18 Treatment of WT
mice with CSP inhibited BLM-induced PAI-1 while aug-
menting uPA and uPAR, and protected the mice against
ATII cell apoptosis and development of PF.7 However, in
uPA- and uPAR-deﬁcient mice, CSP failed to mitigate
PAI-1 expression or apoptosis in ATII cells 3 days after
BLM injury, and they exhibited severe PF when tested 21
days later.7 This is consistent with increased PAI-1, and
inhibition of uPA and uPAR appears to promote ATII cell
apoptosis, EMT, and ﬁbrosis after lung injury in mice.
Our ﬁndings suggest that CSP, an intervention that targets
this pathway, concurrently protects the lung epithelium from
apoptosis7,8 as well as EMT, and prevents PF after BLM-
induced lung injury via uPA-mediated inhibition of PAI-1.
The paradigms that drive ATII cells to these two opposite
fates during lung injury are still unclear. However, we spec-
ulate that EMT is part of a naturally evolving adaptive safe-
guard response to protect ATII cells against apoptosis during65
Marudamuthu et alchronic lung injury. This postulate is supported by the fact that
simultaneous apoptosis and EMT in ATII cells as a result of
endoplasmic reticulum stress contribute to the development of
PF.18,53 In addition, BLM and TGF-b concurrently promote
apoptotic death54 and EMT55e57 in lung epithelial cells, and
apoptosis alone could contribute to the development of PF.7,58
PAI-1, a downstream product of TGF-b, simultaneously
causes apoptosis,7,8,40 senescence,59,60 and EMT61 in diverse
cell types, including ATII cells.
It has been previously reported62 that macrophage surface
activation of TGF-b is dependent on uPAeuPAR-mediated
plasmin generation. However, we found that BLM lung
injury increased active TGF-b in WT and uPA-deﬁcient
mice, which is consistent with ﬁndings of silica-induced
ﬁbrosing injury reported earlier.21,63 In addition, despite
having increased plasminogen activator activity, mice
lacking PAI-1 expression resist EMT and organ
ﬁbrosis.18,64,65 On the contrary, those deﬁcient in uPA and
uPAR expression exhibit accelerated ﬁbrosis7,18,65,66 and
lung-speciﬁc expression of uPA protecting them against
development of PF after BLM injury.67 PAI-1 expression is
disproportionately increased in injured lungs33 and also
induced by TGF-b,23 which in turn irreversibly suppresses
both uPA activity and its steady-state level by PAI-
1emediated turnover of the uPAeuPAR complex. The
protective effects of increased uPA and uPAR may involve
suppression of PAI-1 through increased uPA- and uPAR-
mediated turnover of PAI-1 protein,47 or inhibition of p53
expression and reversal of p53-mediated induction of PAI-1
expression by increased uPA and uPAR,7,44,51,52 or both.
We found that dysregulation of uPA and PAI-1
expression in ATII cells promotes both apoptosis and
EMT after BLM-, TGF-be, or PCS-induced lung injury,
and reversal of these changes by CSP intervention prevents
BLM- and TGF-beinduced EMT and PF.7 Therefore, in-
hibition of EMT by CSP intervention may be associated
with resolution of lung injury. In addition, CSP requires
uPA expression to inhibit BLM-induced PAI-1 and
apoptosis7 or EMT. Thus, dysregulated alveolar ﬁbrino-
lysis, as a result of increased expression of PAI-1 or in-
hibition of uPA and uPAR as a consequence of lung injury,
contributes to ATII cell apoptosis, EMT, and development
of PF. uPA can induce itself or its cell surface receptor,
uPAR,44,68 and inhibit PAI-1 expression,69 which requires
uPA interaction with uPAR. Further, uPA- and uPAR-
deﬁcient mice resist CSP treatment after BLM injury,
whereas CSP is effective in WT mice. We therefore believe
that protection against BLM-induced EMT by CSP re-
quires both uPA and uPAR expression. On the basis of our
recent work,7 we also suspect that the inability of CSP to
mitigate ATII cell EMT, in both uPA- or uPAR-deﬁcient
mice after BLM injury, is due to a lack of uPA-mediated
inhibition of PAI-1 expression. Interestingly, the basal
expression of collagen-I and a-SMA is highly elevated in
PAI-1edeﬁcient ATII cells, which is comparable to or
even higher than that of WT ATII cells exposed to BLM.66However, PAI-1edeﬁcient mice resist spontaneous or
inducible ATII cell apoptosis and development of PF.
Further, protection against development of PF in mice by
transplantation of healthy ATII cells into lungs of mice
with BLM- or silica-induced injury57,63 underscores the
importance of initial ATII cell apoptosis for subsequent
PF. On the basis of these ﬁndings and a recent lineage
study13 using a single-hit BLM model, we believe ATII
cell apoptosis, rather than EMT, mediated by increased
PAI-1 probably plays a dominant role in the subsequent
development of PF. EMT may be a reversible safeguard
mechanism evolved to provide transitory protection
against apoptosis and ATII cell damage through undergo-
ing phenotypic changes without signiﬁcant impact on
PF per se.
Although several pathways could concurrently operate,
our studies indicate a direct role for uPA and PAI-1 in the
process. We provide evidence that supports the role of
activated Src kinase in facilitating BLM- or TGF-
beinduced EMT in ATII cells. PP2 and Y418F mutant Src
kinase attenuated BLM- and TGF-beinduced phosphory-
lation of b-cateninY654 and EMT, and inhibited PAI-
1,24,70e72 while restoring ATII cell uPA expression.
BLM-induced activation of Src kinase and phosphorylation
of caveolin-1 was inhibited by CSP through phosphoryla-
tion of Y527.7 These results suggest a role for increased Src
kinase activation in EMT via induction of PAI-1 and inhi-
bition of uPA and uPAR expression (Figure 7). This sup-
ports the contention that apoptosis and EMT, as a result of
increased PAI-1 by ATII cells, contributes to ﬁbrogenesis
after BLM injury.
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